Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE versus XATMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE versus XATMEP.
METHOTREXATE vs XATMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate antimetabolite; inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate (DHF) to tetrahydrofolate (THF), thereby inhibiting DNA synthesis, repair, and cellular replication. Also inhibits thymidylate synthetase and purine synthesis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby inhibiting DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through inhibition of purine metabolism and adenosine accumulation.
7.5-25 mg orally once weekly; alternatively, 10-25 mg intramuscularly, intravenously, or subcutaneously once weekly.
Methotrexate 10 mg orally once weekly; maximum 25 mg per week.
None Documented
None Documented
Clinical Note
moderateMethotrexate + Digoxin
"Methotrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethotrexate + Digitoxin
"Methotrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethotrexate + Deslanoside
"Methotrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethotrexate + Acetyldigitoxin
"Methotrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3-10 hours (low dose) to 8-15 hours (high dose); clinical context: prolonged to 24-48 hours in renal impairment, third-space effusions, or polyglutamation. Delayed elimination due to enterohepatic recirculation.
The terminal elimination half-life of methotrexate is approximately 3-10 hours for low doses (<50 mg/m²) and 8-15 hours for high doses (≥500 mg/m²). Prolonged half-life (>24 hours) is associated with renal impairment and drug accumulation, increasing toxicity risk.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <10% as metabolites (7-hydroxymethotrexate).
Methotrexate is primarily eliminated renally via glomerular filtration and active tubular secretion. Approximately 80-90% of the dose is excreted unchanged in urine within 24 hours. Fecal excretion is minimal (<10%), with biliary elimination accounting for a small fraction.
Category D/X
Category C
Antimetabolite
Antimetabolite